Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ilex Says Clofarabine Will Go To Oncologic Advisory Committee Dec. 1

This article was originally published in The Pink Sheet Daily

Executive Summary

The announcement follows FDA’s three-month extension of clofarabine’s review deadline. The pediatric leukemia agent is presumably one of two drugs scheduled for review by the Oncologic Drugs Advisory Committee on Dec. 1.

You may also be interested in...

Inex/Enzon’s Marqibo Will Get Oncologic Advisory Cmte. Review Dec. 1, Firms Say

The sponsors are seeking a monotherapy indication for treatment of relapsed aggressive non-Hodgkin’s lymphoma in patients previously treated with at least two combination chemotherapy regimens. The NDA's user fee date is Jan. 15.

FDA Extends Review Deadline For Ilex' Clofarabine

Ilex submits data on 14 additional patients with acute lymphoblastic and acute myeloid leukemia to FDA, extending the user fee date by three months to Dec. 30. The company completed the original rolling NDA March 29.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts